Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569356 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| Ammonia Solution, Strong SCHEMBL3124417 | 0.98 | LMNA (0.51) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL11099209 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL1299996 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL11749172 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL7864102 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL6568208 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL8332808 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL21802444 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA | |
| SCHEMBL7263621 | 0.98 | SIGMAR1 (0.53) | SIGMAR1LMNAPKML3MBTL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | CCR3, CCR5, CCR1 | SIGMAR1 1832/4885LMNA 3837/4885PKM 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.